Trial · NCT05701189
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
NCT05701189, Phase 2, Withdrawn, Chafic Karam
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome. Trials, record NCT05701189. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05701189
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
- NCT number
- NCT05701189
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Chafic Karam
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
- First posted
- 2023-01-27
- Last updated
- 2026-03-12
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Guillain-Barre Syndrome Disability Scale (GBS-DS) | Week 4 | Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome. |
| Primary | Number and seriousness in adverse events in the studied population | Through study completion, an average of 3 years | Safety monitoring |
| Secondary | Guillain-Barre Syndrome Disability Scale (GBS-DS) | 12 and 24 weeks | Scoring system that assesses the functional status of GBS subjects. Scores range from 0 to 6, with higher scores indicating a worse outcome. |
| Secondary | MRC Sum Score | 12 and 24 weeks | Quantifies strength, with a higher score indicating more strength. |
| Secondary | Inflammatory Rasch-Built Overall Disability Scale (I-RODS) | 4, 8, 12, and 24 weeks | Functional outcome assessment. Scores range from 0 to 48, with higher scores indicating a better outcome. |
| Secondary | Number of Days on Respirator | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Number of days in an intensive care unit | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Number of days to hospital discharge | 4, 8, 12, and 24 weeks | as noted in the title |
| Secondary | Mortality | 4, 8, 12, and 24 weeks | Change in vital status |
| Secondary | Percentage of patients with secondary deterioration due to treatment-related fluctuations (TRF) | 4, 8, 12, and 24 weeks | as noted in the title |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05701189
GET https://conductscience.org/api/trials/v1/NCT05701189/registered